Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
X‑linked hypophosphatemic rickets (XLH, OMIM #307800) is a rare genetic metabolic disorder caused by dysregulation of fibroblast-like growth factor 23 (FGF23) leading to profound reduction in renal phosphate reabsorption. Impaired growth, severe rickets and complex skeletal deformities are direct consequences of hypophosphatemia representing major symptoms of XLH during childhood. In adults, secondary complications including early development of osteoarthritis substantially impair quality of life and cause significant clinical burden. With the global approval of the monoclonal FGF23 antibody burosumab, a targeted treatment with promising results in phase III studies is available for children with XLH. Nevertheless, complete phenotypic rescue is rarely achieved and remaining multisystemic symptoms demand multidisciplinary specialist care. Coordination of patient management within the major medical disciplines is a mainstay to optimize treatment and reduce disease burden. This review aims to depict different perspectives in XLH patient care in the setting of a multidisciplinary centre of expertise for rare bone diseases.
Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M. Regulation of serum 1,25(OH)2Vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol. 2011;301(2):F371–7.
Whyte MP, Schranck FW, Armamento-Villareal R. X‑linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab. 1996;81(11):4075–80. PubMed
Sabandal MMI, Robotta P, Bürklein S, Schäfer E. Review of the dental implications of X‑linked hypophosphataemic rickets (XLHR). Clin Oral Invest. 2015;19(4):759–68. CrossRef
Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of Burosumab, an anti-FGF23 antibody, in adults with X‑linked Hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383–93. PubMedCrossRef
Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, et al. Continued beneficial effects of Burosumab in adults with X‑linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271–84. PubMedCrossRef
Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X‑linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res. 2019; https://doi.org/10.1002/jbmr.3843. PubMedPubMedCentralCrossRef
Day AL, Gutiérrez OM, Guthrie BL, Saag KG. Burosumab in tumor-induced osteomalacia: a case report. Joint Bone Spine. 2019; https://doi.org/10.1016/j.jbspin.2019.07.012. PubMedCrossRef
Paley D, Herzenberg JE, Tetsworth K, McKie J, Bhave A. Deformity planning for frontal and sagittal plane corrective osteotomies. Orthop Clin North Am. 1994;25(3):425–65. PubMed
Paley D, Tetsworth K. Mechanical axis deviation of the lower limbs. Preoperative planning of multiapical frontal plane angular and bowing deformities of the femur and tibia. Clin Orthop Relat Res. 1992;280:65–71.
- Multidisciplinary patient care in X‐linked hypophosphatemic rickets: one challenge, many perspectives
Gabriel T. Mindler
- Springer Vienna
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X